Literature DB >> 26911188

Antitumour actions of interferons: implications for cancer therapy.

Belinda S Parker1, Jai Rautela1,2,3, Paul J Hertzog4,5.   

Abstract

The interferons (IFNs) are a family of cytokines that protect against disease by direct effects on target cells and by activating immune responses. The production and actions of IFNs are finely tuned to achieve maximal protection and avoid the potential toxicity associated with excessive responses. IFNs are back in the spotlight owing to mounting evidence that is reshaping how we can exploit this pathway therapeutically. As IFNs can be produced by, and act on, both tumour cells and immune cells, understanding this reciprocal interaction will enable the development of improved single-agent or combination therapies that exploit IFN pathways and new 'omics'-based biomarkers to indicate responsive patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26911188     DOI: 10.1038/nrc.2016.14

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  220 in total

Review 1.  Dynamic control of type I IFN signalling by an integrated network of negative regulators.

Authors:  Rebecca A Porritt; Paul J Hertzog
Journal:  Trends Immunol       Date:  2015-02-25       Impact factor: 16.687

2.  White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma.

Authors:  P de La Salmonière; J J Grob; B Dreno; M Delaunay; C Chastang
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.

Authors:  Wioleta Luszczek; Venugopalan Cheriyath; Tarek M Mekhail; Ernest C Borden
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

4.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

5.  Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.

Authors:  E C Borden; T F Hogan; J G Voelkel
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

6.  Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.

Authors:  Andrea Nicolini; Angelo Carpi
Journal:  Biomed Pharmacother       Date:  2005-06       Impact factor: 6.529

7.  Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.

Authors:  Isaac Yang; Thomas J Kremen; Adrian J Giovannone; Elena Paik; Sylvia K Odesa; Robert M Prins; Linda M Liau
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

8.  Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.

Authors:  E C Borden; J F Holland; T L Dao; J U Gutterman; L Wiener; Y C Chang; J Patel
Journal:  Ann Intern Med       Date:  1982-07       Impact factor: 25.391

9.  Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer.

Authors:  N Kemeny; A Yagoda; Y Wang; K Field; H Wrobleski; W Whitmore
Journal:  Cancer       Date:  1981-11-15       Impact factor: 6.860

10.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

View more
  292 in total

1.  Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Cancer Res       Date:  2020-06-17       Impact factor: 5.852

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

4.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

5.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

6.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

7.  Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown.

Authors:  Hachung Chung; Jorg J A Calis; Xianfang Wu; Tony Sun; Yingpu Yu; Stephanie L Sarbanes; Viet Loan Dao Thi; Abigail R Shilvock; H-Heinrich Hoffmann; Brad R Rosenberg; Charles M Rice
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

8.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Authors:  Angelica Ortiz; Jun Gui; Farima Zahedi; Pengfei Yu; Christina Cho; Sabyasachi Bhattacharya; Christopher J Carbone; Qiujing Yu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Simran Handa; Victor Haas; Susan W Volk; Angela K Brice; Kim Wals; Nicholas J Matheson; Robin Antrobus; Sonja Ludwig; Theresa L Whiteside; Cindy Sander; Ahmad A Tarhini; John M Kirkwood; Paul J Lehner; Wei Guo; Hallgeir Rui; Andy J Minn; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

9.  The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer.

Authors:  Mary R Doherty; Mark W Jackson
Journal:  DNA Cell Biol       Date:  2018-05-11       Impact factor: 3.311

10.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.